---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-188078"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2025-08-26T23:59:59+00:00"
generated_at: "2026-05-17T09:57:48.530984+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Shattuck closes up to $103M private placement, appoints two new directors, cash runway into 2029

## Summary
- Closed private placement of up to ~$103M led by OrbiMed; net proceeds to fund SL-325 through Phase 2 trials.
- Pro forma cash, assuming full warrant exercise, expected to fund operations into 2029.
- Appointed Dr. Daniel Baker (independent director) and Dr. Mona Ashiya (OrbiMed designee) to Board.
- Directors Tyler Brous, Carrie Brownstein, Michael Lee, Kate Sasser resigned upon closing.
- SL-325 (DR3 blocking antibody) IND cleared; Phase 1 trial to start this quarter.

## SEC filing metadata
- accession: 0001193125-25-188078
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2025-08-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000119312525188078/0001193125-25-188078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000119312525188078/d95844d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-188078
- JSON: https://secwatch.observer/filing/0001193125-25-188078.json
- Plain text: https://secwatch.observer/filing/0001193125-25-188078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.